Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 – 10)

Bibliography

• Murata-Hori M, Tatsuka M, Wang YL. Probing the dynamics and functions of aurora B kinase in living cells during mitosis and cytokinesis. Mol Biol Cell 2002;13(4):1099-108
   PubMedGoogle Scholar
• Lu L-Y, Wood JL, Ye L, Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 2008;283(46):31785-90
   PubMedGoogle Scholar
• Vischioni B, Oudejans JJ, Vos W, Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006;5(11):2905-13
   PubMedGoogle Scholar
• Dar AA, Zaika A, Piazuelo MB, Frequent overexpression of aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112(8):1688-98
   PubMedGoogle Scholar
• Smith SL, Bowers NL, Betticher DC, Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005;93(6):719-29
   PubMed Web of Science ®Google Scholar
• Kitajima S, Kudo Y, Ogawa I, Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One 2007;2(9):e944
   Google Scholar
• Harrington EA, Bebbington D, Moore J, VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10(3):262-7
   PubMed Web of Science ®Google Scholar
• Tyler RK, Shpiro N, Marquez R, VX-680 inhibits aurora A and aurora B kinase activity in human cells. Cell Cycle 2007;6(22):2846-54
   PubMedGoogle Scholar
• Gizatullin F, Yao Y, Kung V, The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66(15):7668-77
   PubMedGoogle Scholar
• Wilkinson RW, Odedra R, Heaton SP, AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13(12):3682-8
   PubMed Web of Science ®Google Scholar
• Manfredi MG, Ecsedy JA, Meetze KA, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora A kinase. Proc Natl Acad Sci USA 2007;104(10):4106-11
   PubMed Web of Science ®Google Scholar
• Hardwicke MA, Oleykowski CA, Plant R, GSK1070916, a potent aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009;8(7):1808-17
   PubMed Web of Science ®Google Scholar
• Anderson K, Lai Z, McDonald OB, Biochemical characterization of GSK1070916, a potent and selective inhibitor of aurora B and aurora C kinases with an extremely long residence time1. Biochem J 2009;420(2):259-65
   PubMedGoogle Scholar
• Hoar K, Chakravarty A, Rabino C, MLN8054, a small-molecule inhibitor of aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27(12):4513-25
   PubMed Web of Science ®Google Scholar
• Arbitrario JP, Belmont BJ, Evanchik MJ, SNS-314, a pan-aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 2010;65(4):707-17
   PubMedGoogle Scholar
• VanderPorten EC, Taverna P, Hogan JN, The aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8(4):930-9
   PubMed Web of Science ®Google Scholar
• Tao Y, Leteur C, Calderaro J, The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 2009;8(19):3172-81
   PubMed Web of Science ®Google Scholar
• Yang J, Ikezoe T, Nishioka C, AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110(6):2034-40
   PubMedGoogle Scholar
• Coumar MS, Cheung CH, Chang JY, Advances in aurora kinase inhibitor patents. Expert Opin Ther Pat 2009;19(3):321-56
   PubMedGoogle Scholar
• Cheung CH, Coumar MS, Hsieh HP, Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18(4):379-98
   PubMedGoogle Scholar
• Bebbington D, Binch H, Charrier JD, The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 2009;19(13):3586-92
   PubMedGoogle Scholar
• Traynor AM, Hewitt M, Liu G, Phase I dose escalation study of MK-0457, a novel aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67(2):305-14
   PubMedGoogle Scholar
• Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol 2010;89(11):1081-7
   PubMedGoogle Scholar
• Yao JE, Yan M, Guan Z, Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer 2009;8:95
   PubMedGoogle Scholar
• Cheok CF, Kua N, Kaldis P, Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 2010;17(9):1486-500
   PubMedGoogle Scholar
• Pluim D, Beijnen JH, Schellens JH, Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(29):3549-55
   PubMedGoogle Scholar
• Tomita M, Tanaka Y, Mori N. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer 127(7):1584-94
   PubMedGoogle Scholar
• Gully CP, Zhang F, Chen J, Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer 2010;9:42
   PubMed Web of Science ®Google Scholar
• Aihara A, Tanaka S, Yasen M, The selective aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 2010;52(1):63-71
   PubMedGoogle Scholar
• Nair JS, de Stanchina E, Schwartz GK. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009;15(6):2022-30
   PubMedGoogle Scholar
• Li J, Anderson MG, Tucker LA, Inhibition of aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ 2009;16(3):498-511
   PubMedGoogle Scholar
• Boss DS, Witteveen PO, van der Sar J, Clinical evaluation of AZD1152, an i.v. inhibitor of aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011;22(2):431-7
   PubMedGoogle Scholar
• Kuo CC, Hsieh HP, Pan WY, BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004;64(13):4621-8
   PubMedGoogle Scholar
• Guo J, Anderson MG, Tapang P, Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 2009;9(2):90-102
   PubMedGoogle Scholar
• Carpinelli P, Ceruti R, Giorgini ML, PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6(12 Pt 1):3158-68
   PubMedGoogle Scholar
• Fancelli D, Moll J, Varasi M, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49(24):7247-51
   PubMed Web of Science ®Google Scholar
• Benten D, Keller G, Quaas A, Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11(9):934-44
   PubMed Web of Science ®Google Scholar
• Cohen RB, Jones SF, Aggarwal C, A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15(21):6694-701
   PubMed Web of Science ®Google Scholar
• Steeghs N, Eskens FA, Gelderblom H, Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27(30):5094-101
   PubMedGoogle Scholar
• Nerviano Medical Sciences S.R.L. (IT). WO2010009985A2. 2010
   Google Scholar
• Nerviano Medical Sciences S.R.L. (IT). US20100022553A1. 2010
   Google Scholar
• Nerviano Medical Sciences S.R.L. (IT). WO2010009967A1. 2010
   Google Scholar
• Dar AA, Belkhiri A, Ecsedy J, Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008;68(21):8998-9004
   PubMedGoogle Scholar
• Huck JJ, Zhang M, McDonald A, MLN8054, an inhibitor of aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010;8(3):373-84
   PubMed Web of Science ®Google Scholar
• Sloane DA, Trikic MZ, Chu ML, Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol 2010;5(6):563-76
   PubMedGoogle Scholar
• Dees EC, Infante JR, Cohen RB, Phase 1 study of MLN8054, a selective inhibitor of aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:945-54
   Google Scholar
• Macarulla T, Cervantes A, Elez E, Phase I study of the selective aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010;9(10):2844-52
   PubMed Web of Science ®Google Scholar
• Sells TB, Ecsedy JA, Stroud SG. MLN8237: an orally active small molecule inhibitor of aurora A kinase in phase I clinical trials. AACR Annual Meeting (Meeting abstracts); 12 – 16 April 2008; San Francisco, CA, USA
   Google Scholar
• Gorgun G, Calabrese E, Hideshima T, A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115(25):5202-13
   PubMed Web of Science ®Google Scholar
• Maris JM, Morton CL, Gorlick R, Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55(1):26-34
   PubMed Web of Science ®Google Scholar
• Wang S, Midgley CA, Scaerou F, Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 2010;53(11):4367-78
   PubMedGoogle Scholar
• Oslob JD, Heumann SA, Yu CH, Water-soluble prodrugs of an aurora kinase inhibitor. Bioorg Med Chem Lett 2009;19(5):1409-12
   PubMedGoogle Scholar
• Zhong M, Bui M, Shen W, 2-Aminobenzimidazoles as potent aurora kinase inhibitors. Bioorg Med Chem Lett 2009;19(17):5158-61
   PubMedGoogle Scholar
• Adams ND, Adams JL, Burgess JL, Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase. J Med Chem 2010;53(10):3973-4001
   PubMedGoogle Scholar
• Jani JP, Arcari J, Bernardo V, PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9(4):883-94
   PubMed Web of Science ®Google Scholar
• Bray MR. ENMD-2076, an oral aurora A and angiogenesis kinase inhibitor. AACR Annual Meeting (Meeting abstracts); 12 – 16 April 2008; San Franciso, CA, USA
   Google Scholar
• Wang S, Midgley CA, Scaerou F, Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 2010;53(11):4367-78
   PubMedGoogle Scholar
• Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010;16(11):2989-98
   PubMed Web of Science ®Google Scholar
• Yee KWL. A phase I study of ENMD-2076 in patients with relapsed or refractory leukemia. ASH Annual Meeting and Exposition (Meeting abstracts); 4 – 7 December 2010; Orlando, FL, USA
   Google Scholar
• Howard S, Berdini V, Boulstridge JA, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52(2):379-88
   PubMedGoogle Scholar
• Tanaka R, Squires MS, Kimura S, Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010;116(12):2089-95
   PubMed Web of Science ®Google Scholar
• Kristeleit R. A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. ASCO Annual Meeting (Meeting abstracts); 29 May – 2 June 2009; Orlando, FL, USA
   Google Scholar
• McLaughlin J, Markovtsov V, Li H, Preclinical characterization of aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136(1):99-113
   PubMedGoogle Scholar
• Shimomura T, Hasako S, Nakatsuru Y, MK-5108, a highly selective aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 2010;9(1):157-66
   PubMed Web of Science ®Google Scholar
• Payton MN, Bush TL, Chung G, Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70(23):9846-54
   PubMed Web of Science ®Google Scholar
• Gurtler U, Tontsch-Grunt U, Jarvis M, Effect of BI 811283, a novel inhibitor of aurora B kinase, on tumor senescence and apoptosis. J Clin Oncol 2010;28(Suppl): abstract e13632
   Google Scholar
• Scheulen ME, Mross KB, Richly H, A phase I dose-escalation study of BI 811283, an aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl): abstract e13065
   Google Scholar
• Smith DC, Britten C, Garon EB, A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. J Clin Oncol 2010;28 (15 Suppl): abstract 3105
   Google Scholar
• Abbott Laboratories. WO2010065825A2. 2010
   Google Scholar
• Banyu Pharmaceutical Co. WO2009104802A1. 2009
   Google Scholar
• Banyu Pharmaceutical Co. Ltd. WO08026768A1. 2008
   Google Scholar
• Banyu Pharmaceuticals and Vertex Pharmaceuticals. WO2010111050A1. 2010
   Google Scholar
• Banyu Pharmaceuticals and Vertex Pharmaceuticals. WO2010111056A1. 2010
   Google Scholar
• Banyu Pharmaceuticals and Vertex Pharmaceuticals. WO2010111057A1. 2010
   Google Scholar
• Merck Serono S.A. WO2009108670A1. 2009
   Google Scholar
• Merck Serono S.A. WO2010002779A2. 2010
   Google Scholar
• Merck Patent GmbH. WO2010077530A1. 2010
   Google Scholar
• Merck Serono S.A. WO2010028116A1. 2010
   Google Scholar
• National Health Research Institutes. WO2009134658A2. 2009
   Google Scholar
• National Health Research Institutes. WO2010036629A2. 2010
   Google Scholar
• Coumar MS, Tsai MT, Chu CY, Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor. ChemMedChem 2010;5(2):255-67
   PubMedGoogle Scholar
• Coumar MS, Chu CY, Lin CW, Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 2010;53(13):4980-8
   PubMedGoogle Scholar
• Schering Corp. & Albany Molecular Research. WO2009097233A1. 2009
   Google Scholar
• Schering Corp. WO2009017701A1. 2009
   Google Scholar
• University Health Network. WO2009079767A1. 2009
   Google Scholar
• University Health Network. WO2010115279A1. 2010
   Google Scholar
• Arrow Therapeutics Ltd. WO2009063240A1. 2009
   Google Scholar
• Bayer Healthcare LLC. WO2009042543A1. 2009
   Google Scholar
• Curis, Inc. WO2009086012A1. 2009
   Google Scholar
• Mikana Therapeutics, Inc. WO2010062848A1. 2010
   Google Scholar
• Shanghai Genomics, Inc. WO2010051781A1. 2010
   Google Scholar
• Telik, Inc. WO2010036873A1. 2010
   Google Scholar
• Universitaet Leipzig, Fundacio Privada Centre de Regulacio Genomica and Institucio Catalana de Recerca I Estudis Avancats. WO2010081881A1. 2010
   Google Scholar
• Vitae Pharmaceuticals, Inc. WO2009111028A1. 2009
   Google Scholar
• Jackson JR, Patrick DR, Dar MM, Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7(2):107-17
   PubMedGoogle Scholar
• Nerviano Medical Sciences S.r.l. US20100022553A1. 2010
   Google Scholar
• Nerviano Medical Sciences S.r.l. WO2010009967A1. 2010
   Google Scholar
• Moore AS, Blagg J, Linardopoulos S, Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24(4):671-8
   PubMedGoogle Scholar
• Mahboobi S, Dove S, Sellmer A, Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. J Med Chem 2009;52(8):2265-79
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. WO2009012312A1. 2009
   Google Scholar
• Abbott Laboratories. WO2009136966A1. 2009
   Google Scholar